PDF herunterladen
Dtsch Med Wochenschr 2013; 138(40): 2037-2040
DOI: 10.1055/s-0033-1349573
Rheumatologie | Commentary
Rheumatologie
© Georg Thieme Verlag KG Stuttgart · New York

Psoriasis-Arthritis und allgemeine Empfehlungen zur zielgenauen Behandlung der Spondyloarthritiden

Psoriatic arthritis and general recommendations for targeted therapy of spondyloarthritis
E. Märker-Hermann
1   Klinik Innere Medizin IV (Rheumatologie, Klinische Immunologie, Nephrologie), HSK Dr. Horst Schmidt Klinik GmbH, Wiesbaden
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
24. September 2013 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Schlüsselwörter

Spondyloarthritis - Psoriasis-Arthritis - zielgerichtete Therapie

Keywords

spondyloarthritis - psoriatic arthritis - treat to target
 

  • Literatur

  • 1 Behrens F, Finkenwirth C, Pavelka K et al. Leflunomide in psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res 2013; 65: 464-470
    PubMedGoogle Scholar
  • 2 Filer C, Ho P, Smith RL et al. Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum 2008; 58: 3705-3709
    CrossrefPubMedGoogle Scholar
  • 3 Gossec L, Smolen JS, Gaujoux-Viala C et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therap. Ann Rheum Dis 2012; 71: 4-12
    CrossrefPubMedGoogle Scholar
  • 4 Jamnitski A, Symmons D, Peters MJ et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 2013; 72: 211-216
    CrossrefPubMedGoogle Scholar
  • 5 Kingsley GH, Kowalczyk A, Taylor H et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 2012; 51: 1368-1377
    CrossrefPubMedGoogle Scholar
  • 6 Li WQ, Han JL, Manson JE et al. Psoriasis and risk of non-fatal cardiovascular disease in US women: a cohort study. Br J Dermatol 2012; 166: 811-818
    CrossrefPubMedGoogle Scholar
  • 7 McInnes I, Kavanaugh A, Gottlieb AB et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382: 780-789
    CrossrefPubMedGoogle Scholar
  • 8 Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684
    CrossrefPubMedGoogle Scholar
  • 9 Rudwaleit M, van der Heijde D, Landewe R et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68: 777-783
    CrossrefPubMedGoogle Scholar
  • 10 Rudwaleit M, van der Heijde D, Landewé R et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011; 70: 25-31
    CrossrefPubMedGoogle Scholar
  • 11 Schett G, Wollenhaupt J, Papp K et al. Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012; 64: 3156-3167
    CrossrefPubMedGoogle Scholar
  • 12 Smolen J, Braun J, Dougados M et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2013; Jun 8. [Epub ahead of print]
    PubMedGoogle Scholar
  • 13 Van Praet L, Van den Bosch FE, Jacques P et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 2013; 72: 414-417
    CrossrefPubMedGoogle Scholar